Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Chromosome 5q deletions combined with TP53 mutations drive stepwise aneuploid evolution in complex karyotype AML, unveiling shared transcriptional vulnerabilities exploitable by targeted therapies like BCL2 inhibition with venetoclax.
The GCLLSG CLL12 trial reveals ibrutinib’s event-free survival benefits in specific genetic subgroups of early-stage CLL, while affirming watch-and-wait as standard for high-risk patients with del(17p) and TP53 mutations.
This multicenter study reveals that recent mechanical venous thrombosis risk factors markedly increase the risk of cryptogenic ischemic stroke in young adults, especially in those under 40 and with patent foramen ovale, independent of throm
This multicenter study reveals that recent mechanical venous thrombosis risk factors within 14 days significantly increase the risk of cryptogenic ischemic stroke in young adults, notably in those under 40 and with patent foramen ovale, ind
This study examines the impact of biosimilar introduction on cancer biologics, highlighting reduced costs and market share for originator biologics, benefiting both payers and patients.
Baseline plasma levels of CPVL and PIGR correlate with anthracycline-induced systolic dysfunction, offering potential early biomarkers for cardiotoxicity in hematologic malignancy patients undergoing chemotherapy.
Ivosidenib monotherapy demonstrates substantial efficacy and safety in IDH1 mutated myelodysplastic neoplasm, especially in treatment-naïve high-risk patients, offering a new therapeutic option.
DNA methylation profiling in AML patients reveals epigenetic subtypes that mirror genetic mutations, improving risk stratification and outcome prediction beyond standard genetic markers.
This study reveals distinct clinical associations of IL-12p40 and IL-18 in severe fibrosing chronic graft-versus-host disease, highlighting their differing impacts on relapse risk, survival, and immune responses post-allogeneic stem cell tr
This article explores how oncology clinicians perceive and manage the burden patients face when involved in treatment decisions, highlighting varied clinician approaches to balance patient autonomy with emotional support in shared decision
This study analyzes EBV infection and PTLD incidence in pediatric haploidentical HSCT, identifying prior CAR-T therapy, CMV viremia, and TBI conditioning as significant risk factors, with implications for enhanced monitoring and preemptive
A phase 1 trial of soquelitinib, a selective ITK inhibitor, showed favorable safety and encouraging efficacy with Th1-skewing immunomodulation in relapsed/refractory peripheral T cell lymphomas, highlighting a novel therapeutic approach.
Spatial multimodal profiling reveals two macrophage-defined ENKTL subgroups with distinct tumor-myeloid interactions influencing prognosis and potential immunotherapy targets.
A novel B-cell acute lymphoblastic leukemia subtype characterized by IGH::FENDRR rearrangement and KRAS mutations shows distinct molecular features and poor response to standard chemotherapy, highlighting the need for early immunotherapy an
This retrospective multicenter study evaluates fecal microbiota transplantation (FMT) for steroid-refractory acute graft-versus-host disease (aGvHD), demonstrating a 60.5% response at day 28 and highlighting FMT’s potential as a safe
This article explores how T-cell immunosenescence impairs the efficacy of CD19 CAR T-cell therapy in chronic lymphocytic leukemia, highlighting potential therapeutic strategies to overcome this barrier.
TP53-mutant clonal hematopoiesis in CAR T-cell recipients is linked to a pro-inflammatory state, cytopenias, and worse survival, highlighting the importance of tailored monitoring strategies in this high-risk group.
The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients
This review synthesizes key epidemiologic evidence linking transfusion-related allergic reactions with alpha-gal syndrome (AGS), revealing significant risk in blood type O recipients of B or AB plasma/platelets in AGS-endemic regions.
This retrospective study compares treosulfan and busulfan combined with clofarabine as reduced intensity conditioning before allogeneic transplant in adults with myeloid malignancies, highlighting faster neutrophil recovery and improved sur
Open language-specific specialty feeds and department pages.